References
Kalita J, Kohat AK, Misra UK (2014) Predictors of outcome of myasthenic crisis. Neurol Sci 35:1109–1114
Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475–490
Zouvelou V, Zisimopoulou P, Psimenou E et al (2014) AChR-myasthenia gravis switching to double-seropositive several years after the onset. J Neuroimmunol 267:111–112
Zhang B, Tzartos JS, Belimezi M et al (2012) Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 69:445–451
Zisimopoulou P, Evangelakou P, Tzartos J et al (2013) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. doi:10.1016/j.jaut.2013.12.004
Romi F, Skeie GO, Aarli JA et al (2000) The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol 57:1596–1600
Yu S, Lin J, Fu X et al (2014) Risk factors of myasthenic crisis after thymectomy in 178 generalized myasthenia gravis patients in a five-year follow-up study. Int J Neurosci (Epub ahead of print)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, N., Liu, Q., Wu, X. et al. Predictors of outcome of myasthenic crisis. Neurol Sci 36, 801–802 (2015). https://doi.org/10.1007/s10072-014-1906-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-014-1906-2